Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CCR5 | P51681 | 1/20 | 0.54 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20561885 | 0.79 | HTT (0.58) | CCR1RAB9ACCR5SMN1; SMN2HTT | |
| SCHEMBL4429156 | 0.78 | KDM4E (0.44) | SMN1; SMN2HTTGAATDP1L3MBTL1 | |
| SCHEMBL22762128 | 0.76 | MAPT (0.57) | CCR1CCR5SMN1; SMN2HTTTDP1 | |
| SCHEMBL13561656 | 0.76 | CYP1A2 (0.44) | CCR1RAB9ACCR5SMN1; SMN2HTT | |
| SCHEMBL15045457 | 0.73 | CCR1 (0.50) | CCR1RAB9ACCR5METAP2SMN1; SMN2 | |
| SCHEMBL890081 | 0.72 | CCR1 (0.42) | CCR1RAB9ACCR5CYP1A2KDM4E | |
| Neocuproine SCHEMBL29367091 | 0.72 | CCR1 (1.00) | CCR1RAB9ACCR5METAP2TDP1 | |
| Neocuproine SCHEMBL29639703 | 0.72 | CCR1 (1.00) | CCR1RAB9ACCR5METAP2TDP1 | |
| Neocuproine SCHEMBL124563 | 0.72 | CCR1 (1.00) | CCR1RAB9ACCR5METAP2TDP1 | |
| Neocuproine SCHEMBL11672280 | 0.72 | CCR1 (1.00) | CCR1RAB9ACCR5METAP2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796705-B2 | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2014108430-A1 | THERMALLY ACTIVATED FLUORESCENCE AND SINGLET HARVESTING WITH RIGID METAL COMPLEXES FOR OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2014-07-17 | — | — | WO | disclosed |
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | SCHERING CORPORATION | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | HAVCR2, ELOC, ZC3HAV1 | CCR1 420/4885RAB9A 3293/4885CCR5 465/4885 |
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | ZC3HAV1, HAVCR2, ZC3HAV1L | CCR1 423/4885RAB9A 1539/4885CCR5 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.